Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432703 · ClinicalTrials.gov registry record · Phase 2
A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder
A Phase 2 study of Phobic Disorders, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT02432703 is a Phase 2 study of Phobic Disorders that has completed, run by Janssen Research & Development. The registered enrollment target is 150 participants, above the 91-participant average among 5 other Phobic Disorders trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT02432703, a Phase 2 study of Phobic Disorders, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG JNJ-42165279
Study Locations (20)
Other
- - Adelaide
- - Frankston
- - Melbourne
- - Perth
New York
- - New York
- - Rochester
- - Staten Island
Massachusetts
- - Boston
- - Natick
Pennsylvania
- - Allentown
- - Reading
Ontario
- - Hamilton
- - Mississauga
California
- - La Jolla
Connecticut
- - Hartford
Florida
- - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2015-06-11 |
| Est. Completion | 2018-08-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02432703
The ClinicalTrials.gov registry entry for NCT02432703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 91-participant average among 5 other Phobic Disorders trials with a reported enrollment target (65% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Phobic Disorders appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02432703 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02432703 about?
NCT02432703 is a clinical study titled "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder". The purpose of this study is to investigate the efficacy of JNJ-42165279 during 12 weeks of treatment in participants with Social Anxiety Disorder (SAD).
What is the current status of trial NCT02432703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2015-06-11. Estimated completion is 2018-08-09.
What conditions does trial NCT02432703 study?
This clinical trial studies the following conditions: Phobic Disorders.
What interventions are being tested in trial NCT02432703?
The interventions under investigation include: Placebo (DRUG), JNJ-42165279 (DRUG).
Who is sponsoring clinical trial NCT02432703?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02432703 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Phobic Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia
COMPLETED · Phase 2
-
St. John's Wort Versus Placebo in Social Phobia
COMPLETED · Phase 2
-
Reward Processing and Exposure Therapy for Social Anxiety Disorder
RECRUITING · NA
-
Treatment for Specific Phobias in Children
COMPLETED · Phase 1
-
Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.